Open AccessProstate cancer – major changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Author(s) -
Buyyounouski Mark K.,
Choyke Peter L.,
McKenney Jesse K.,
Sartor Oliver,
Sandler Howard M.,
Amin Mahul B.,
Kattan Michael W.,
Lin Daniel W.
Publication year - 2017
Publication title -
ca: a cancer journal for clinicians
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 62.937
H-Index - 168
eISSN - 1542-4863
pISSN - 0007-9235
DOI - 10.3322/caac.21391
Subject(s) - medicine , prostate cancer , grading (engineering) , cancer , stage (stratigraphy) , cancer staging , oncology , prostatectomy , disease , gynecology , paleontology , civil engineering , engineering , biology
Answer questions and earn CME/CNE The eighth edition of the American Joint Committee on Cancer (AJCC) tumor‐node‐metastasis (TNM) Staging Manual has been updated and improved to ensure the highest degree of clinical relevance and to improve its utility for patient evaluation and clinical research. Major changes include: 1) pathologically organ‐confined disease is now considered pT2 and is no longer subclassified by extent of involvement or laterality, 2) tumor grading now includes both the Gleason score (as in the seventh edition criteria) and the grade group (introduced in the eighth edition criteria), 3) prognostic stage group III includes select, organ‐confined disease based on prostate‐specific antigen and Gleason/grade group status, and 4) 2 statistical prediction models are included in the staging manual. The AJCC will continue to critically analyze emerging prostate cancer biomarkers and tools for their ability to prognosticate and guide treatment decision making with the highest level of accuracy and confidence for patients and physicians. CA Cancer J Clin 2017;67:245–253 . © 2017 American Cancer Society .